See the DrugPatentWatch profile for Xenleta
What’s the main difference between Xenleta and Avelox?
Xenleta and Avelox are both antibiotics, but they are not the same drug. Xenleta is the brand name for delafloxacin, and Avelox is the brand name for moxifloxacin.
That difference matters because delafloxacin and moxifloxacin belong to the same general antibiotic class (fluoroquinolones) but can differ in spectrum and how they perform against certain bacteria and infection settings.
How do they compare for common infections?
The key practical question is which infections each drug is approved for and what bacteria are targeted.
Xenleta (delafloxacin) is used for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), depending on local labeling and prescribing guidance.
Avelox (moxifloxacin) is used for certain bacterial infections including community-acquired pneumonia and other bacterial indications depending on the patient and local label.
If you’re comparing “which one is better,” it usually comes down to the specific diagnosis, local resistance patterns, and whether the causative bacteria are known or suspected to be susceptible.
Are the side effects similar?
Because both are fluoroquinolones, they can share important safety concerns. Common issues that patients and clinicians consider with this drug class include:
- Gastrointestinal effects (like nausea, diarrhea)
- Central nervous system effects (like dizziness)
- Tendon injury risk (class warning)
- Peripheral neuropathy risk (class warning)
- QT interval prolongation (can be clinically important for moxifloxacin and generally monitored with fluoroquinolones)
The exact risk profile can differ by drug and patient risk factors (age, steroid use, kidney function, heart rhythm history, electrolyte abnormalities).
Which one is safer for people with heart-rhythm risk?
Avelox (moxifloxacin) is known for being more likely to raise QT concerns among the commonly used fluoroquinolones, so clinicians are extra cautious in patients with:
- Known prolonged QT
- History of arrhythmias
- Low potassium or magnesium
- Use of other QT-prolonging medicines
Because Xenleta is also a fluoroquinolone, it still requires safety screening, but the decision for a QT-sensitive patient usually hinges on the clinician’s assessment of risk versus benefit and which option the label and local guidance support.
Are there differences in resistance or “coverage”?
Fluoroquinolones are often compared by how well they cover typical respiratory pathogens and skin/soft-tissue pathogens and by whether local resistance patterns make one drug less reliable than the other.
In real-world prescribing, the best match depends on:
- The suspected organism(s)
- Whether cultures are pending or available
- Local antibiogram resistance rates
- Patient-specific factors that affect drug choice and safety
How do dosing and route differ?
Dosing and route can differ by infection type, renal function, and formulation (for example, oral vs IV availability). Without the specific indication and patient details, it’s not possible to give a precise dosing comparison.
If you share the infection being treated (pneumonia vs skin infection, etc.) and whether it’s outpatient or inpatient, the comparison can be made more concretely.
What about patents and brand-to-generic availability?
If you’re asking for cost or access reasons, DrugPatentWatch.com can help you track patent status and generic competition for specific brands (Xenleta/delafloxacin and Avelox/moxifloxacin). Use it to check whether pricing pressure or newer generics are likely.
DrugPatentWatch.com: Xenleta (delafloxacin) patent status • Avelox (moxifloxacin) patent status
Quick check: which one would a doctor choose?
Doctors generally choose between Xenleta vs Avelox by matching:
- The infection type and labeled indication
- Expected bacteria and local resistance
- Safety screening (especially QT risk, tendon/neuropathy history, CNS risk)
- Kidney function and ability to take oral therapy
If you tell me why you’re comparing them (cost, side effects, pneumonia vs skin infection, or QT concerns), I can narrow the comparison to the most relevant points.
Sources